Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial
Citius Pharmaceuticals Inc (NASDAQ:CTXR) reported topline results from the Phase 3 trial of I/ONTAK (E7777) for persistent or recurrent cutaneous T-cell…
Citius Pharmaceuticals Announces FDA Acceptance Of IND Application For Its Phase 2b Study Of Halo-Lido For Prescription Treatment Of Hemorrhoids
Study expected to begin enrolling patients in the first half of 2022
Hemorrhoids affect approximately 5% of the US population, with more than 10 million patients annually reporting symptoms
CRANFORD, N.J., Feb. 15, 2022
Citius Pharmaceuticals: Q1 Earnings Insights
Citius Pharmaceuticals (NASDAQ:CTXR) reported its Q1 earnings results on Thursday, February 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Citius Pharmaceuticals reported in-line EPS of $-0.06 versus an estimate of $-0.06.
Citius Pharmaceuticals Q1 EPS $(0.06) Up From $(0.15) YoY
Citius Pharmaceuticals (NASDAQ:CTXR) reported quarterly losses of $(0.06) per share. This is a 60 percent increase over losses of $(0.15) per share from the same period last year.
Top 10 Trending Penny Stocks for Friday, Feb. 4, 2022 (Sentiment via Swaggy Stocks)
SOC Telamed (TLMD)
Exela Technologies (XELA)
Senseonics (SENS)
Applied Genetic Technologies (AGTC)
Reed's (REED)
Citius Pharmaceuticals (CTXR)
OceanPal (OP)
Exicure (XCUR)
Veru (VERU)
Gran Tierra Energy
Maxim Group Initiates Coverage On Citius Pharmaceuticals with Buy Rating, Announces Price Target of $4
Maxim Group analyst Michael Okunewitch initiates coverage on Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy rating and announces Price Target of $4.
Citius Pharmaceuticals Shares Move Higher, Co. Says To Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that it will host a webcast on October 20, 2021 at 8:30 a.m.
Benzinga Announces The 8 ‘Rising Star’ Companies Being Featured On Its Next ‘All Access’ Show
Benzinga is thrilled to announce the guest lineup for our next All Access show, set to air Thursday, October 7 at 9:00 am ET.
Why This Citius Analyst Thinks The Biopharma’s Shares Present 375% Upside Potential
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced earlier this week an agreement with Dr.